Barclays PLC reiterated their overweight rating on shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in a report published on Thursday. Barclays PLC currently has a $105.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $80.00.

ALNY has been the topic of a number of other reports. ValuEngine raised shares of Alnylam Pharmaceuticals from a strong sell rating to a sell rating in a report on Friday, June 2nd. Jefferies Group LLC set a $102.00 target price on shares of Alnylam Pharmaceuticals and gave the company a buy rating in a report on Friday, August 25th. Piper Jaffray Companies set a $116.00 target price on shares of Alnylam Pharmaceuticals and gave the company a buy rating in a report on Wednesday, May 24th. BidaskClub raised shares of Alnylam Pharmaceuticals from a buy rating to a strong-buy rating in a report on Saturday, August 5th. Finally, Credit Suisse Group set a $96.00 target price on shares of Alnylam Pharmaceuticals and gave the company a buy rating in a report on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have issued a buy rating to the stock. Alnylam Pharmaceuticals currently has a consensus rating of Buy and a consensus target price of $83.79.

Shares of Alnylam Pharmaceuticals (NASDAQ ALNY) traded up 1.09% during midday trading on Thursday, hitting $73.32. The stock had a trading volume of 984,993 shares. The company’s 50 day moving average price is $82.17 and its 200-day moving average price is $67.35. The firm’s market capitalization is $6.73 billion. Alnylam Pharmaceuticals has a 1-year low of $31.38 and a 1-year high of $89.45.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($1.22) by $0.12. The business had revenue of $15.93 million for the quarter, compared to the consensus estimate of $23.86 million. Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The company’s quarterly revenue was up 82.9% compared to the same quarter last year. During the same period last year, the firm earned ($1.05) earnings per share. Equities analysts predict that Alnylam Pharmaceuticals will post ($5.18) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/09/08/alnylam-pharmaceuticals-alny-overweight-rating-reaffirmed-at-barclays-plc.html.

Several hedge funds and other institutional investors have recently bought and sold shares of ALNY. Teachers Advisors LLC boosted its position in shares of Alnylam Pharmaceuticals by 10.6% during the 4th quarter. Teachers Advisors LLC now owns 73,576 shares of the biopharmaceutical company’s stock worth $2,755,000 after acquiring an additional 7,048 shares in the last quarter. Bank of Montreal Can boosted its position in shares of Alnylam Pharmaceuticals by 283.6% during the 1st quarter. Bank of Montreal Can now owns 9,528 shares of the biopharmaceutical company’s stock worth $488,000 after acquiring an additional 7,044 shares in the last quarter. Nisa Investment Advisors LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter worth approximately $256,000. Nationwide Fund Advisors boosted its position in shares of Alnylam Pharmaceuticals by 30.5% during the 1st quarter. Nationwide Fund Advisors now owns 11,583 shares of the biopharmaceutical company’s stock worth $594,000 after acquiring an additional 2,707 shares in the last quarter. Finally, First Manhattan Co. acquired a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter worth approximately $135,000. Institutional investors and hedge funds own 94.27% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.